⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28818661 | 0.97 | — | — | |
| SCHEMBL275276 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL5860637 | 0.86 | — | — | |
| SCHEMBL382097 | 0.80 | — | — | |
| SCHEMBL2332294 | 0.77 | — | — | |
| Phosphoric Acid SCHEMBL1936777 | 0.75 | — | — | |
| SCHEMBL23904675 | 0.74 | MAPT (0.38) | — | |
| SCHEMBL26932633 | 0.67 | — | — | |
| SCHEMBL21225200 | 0.65 | — | — | |
| SCHEMBL28958432 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4511372-A1 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | Mirati Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2023205074-A1 | PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB | Mirati Therapeutics, Inc. (US) | 2023-10-26 | — | — | WO | claimed |
| WO-2025098391-A9 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| US-12398147-B2 | Macrocyclic spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2025108154-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | HUAHUI HEALTH LTD. (CN) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025098391-A1 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-05-15 | — | — | WO | disclosed |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-2025034951-A1 | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20240368096-A1 | Fused Heterobicyclic Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2024-11-07 | — | — | US | disclosed |
| WO-2024182271-A1 | FUSED HETEROTETRACYCLIC ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-4376834-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-108359001-A | Conotoxin mutant polypeptides lv1c-AA and application and preparation method | 华南农业大学 | 2018-08-03 | — | — | CN | disclosed |
| WO-2018098411-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-3284851-A1 | METHOD FOR SOLID-PHASE SYNTHESIS OF DNA-ENCODED CHEMICAL LIBRARY | Hitgen Ltd. (CN) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017006295-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-01-12 | — | — | WO | disclosed |
| CN-106243037-A | The substituted phenylurea of part and phenyl amide as Rhizoma et radix valerianae compounds receptor | 格吕伦塔尔有限公司 | 2016-12-21 | — | — | CN | disclosed |
| EP-3092233-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-11-16 | — | — | EP | disclosed |
| WO-2015104684-A1 | HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-07-16 | — | — | WO | disclosed |
| CN-1460023-A | Polymer modified bioactive synthetic chemokines and methods of production and use | GRYPHON TREAT CO (US) | 2003-12-03 | — | — | CN | disclosed |
| CN-1271279-A | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LTD (GB) | 2000-10-25 | — | — | CN | disclosed |